$26.70
0.15% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
BMG5269C1010
Symbol
KNSA
Sector
Industry

Kiniksa Pharmaceuticals Ltd. Class A Stock price

$26.70
+6.65 33.17% 1M
+5.49 25.88% 6M
+6.92 34.98% YTD
+7.03 35.74% 1Y
+18.06 209.03% 3Y
+5.04 23.27% 5Y
+7.23 37.13% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.04 0.15%
ISIN
BMG5269C1010
Symbol
KNSA
Sector
Industry

Key metrics

Market capitalization $1.95b
Enterprise Value $1.69b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 38.64
EV/Sales (TTM) EV/Sales 3.51
P/S ratio (TTM) P/S ratio 4.05
P/B ratio (TTM) P/B ratio 4.25
Revenue growth (TTM) Revenue growth 59.45%
Revenue (TTM) Revenue $481.17m
EBIT (operating result TTM) EBIT $-15.80m
Free Cash Flow (TTM) Free Cash Flow $43.73m
Cash position $268.34m
EPS (TTM) EPS $-0.24
P/E forward 36.08
P/S forward 3.25
EV/Sales forward 2.82
Short interest 8.54%
Show more

Is Kiniksa Pharmaceuticals Ltd. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Kiniksa Pharmaceuticals Ltd. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

Buy
100%

Financial data from Kiniksa Pharmaceuticals Ltd. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
481 481
59% 59%
100%
- Direct Costs 220 220
103% 103%
46%
261 261
35% 35%
54%
- Selling and Administrative Expenses 171 171
27% 27%
36%
- Research and Development Expense 104 104
21% 21%
22%
-14 -14
49% 49%
-3%
- Depreciation and Amortization 1.57 1.57
43% 43%
0%
EBIT (Operating Income) EBIT -16 -16
48% 48%
-3%
Net Profit -17 -17
296% 296%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Kiniksa Pharmaceuticals Ltd. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kiniksa Pharmaceuticals Ltd. Class A Stock News

Positive
Seeking Alpha
15 days ago
Kiniksa Pharmaceuticals posted strong Q1 results last week, beating expectations and raising 2025 ARCALYST net sales guidance to $590-$605 million, up from $560-$580 million. Analyst firms are optimistic, with firms like Goldman Sachs, Wedbush, and Jefferies assigning Buy ratings and price targets ranging from $32 to $45 on the shares. Kiniksa also has a solid balance sheet with nearly $270 mil...
Neutral
GlobeNewsWire
21 days ago
– Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory disease of the heart that is often underdiagnosed or misdiagnosed –
Neutral
Seeking Alpha
21 days ago
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q1 2025 Results Conference Call April 29, 2025 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman & Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Mary Kate - Citi Roger Song -...
More Kiniksa Pharmaceuticals Ltd. Class A News

Company Profile

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.

Head office Bermuda
CEO Sanj Patel
Employees 315
Founded 2015
Website www.kiniksa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today